InvestSMART

Radiopharm Theranostics Limited (ASX:RAD)

ALERT: Price-sensitive ASX Announcement for RAD
Current share price for RAD : $0.010 -0.011 (-52.38%)+
Announcement
Release
16 Apr 2026 8:41AM
Price at Release
$0.021
Full Release
download
Summary
Radiopharm Theranostics Limited announced the completion of enrolment for its U.S. Phase 2b imaging trial of RAD 101, aimed at diagnosing brain metastases. RAD 101 targets fatty acid synthase (FASN), which is overexpressed in many solid tumors, to improve the detection of cancer cells. The trial, involving 30 individuals with confirmed brain metastases, has shown a 90% concordance with MRI, reinforcing confidence in its potential. The company intends to advance RAD 101 to a Phase 3 pivotal trial and has received FDA Fast Track Designation. The full data readout is anticipated by June 2026.
Key Points
  • Radiopharm Theranostics Limited has completed enrolment for its Phase 2b imaging trial of RAD 101.
  • The trial focuses on diagnosing brain metastases with a primary endpoint of concordance with MRI.
  • RAD 101 targets fatty acid synthase (FASN) overexpressed in many solid tumors.
  • The trial involves 30 individuals with confirmed brain metastases from various solid tumors.
  • RAD 101 has received FDA Fast Track Designation.
  • The company is aiming to advance RAD 101 to a U.S. Phase 3 pivotal trial.
  • Interim data shows RAD 101 has a 90% concordance with MRI.
  • The full data readout is expected in June 2026.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.